Search

Axsome Therapeutics Inc

Затворен

СекторЗдравеопазване

207.75 -2.66

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

206.19

Максимум

213.31

Ключови измерители

By Trading Economics

Приходи

13M

-51M

Продажби

27M

218M

EPS

-0.99

Марж на печалбата

-23.498

Служители

1,346

EBITDA

11M

-50M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+35.8% upside

Дивиденти

By Acuity

Следващи печалби

2.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

485M

11B

Предишно отваряне

210.41

Предишно затваряне

207.75

Настроения в новините

By Acuity

7%

93%

2 / 339 Класиране в Healthcare

Axsome Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.09.2026 г., 19:46 ч. UTC

Axsome Therapeutics Inc shares fell after reaching an early high, remaining below Thursday's close and stabilizing around the middle of its one-month trading range.

16.09.2026 г., 20:10 ч. UTC

Macro Event

Axsome Therapeutics Inc is advancing amid broader market reactions to the Federal Reserve's 25 basis point interest rate hike, consolidating gains above its 20-day moving average.

15.09.2026 г., 21:01 ч. UTC

Axsome Therapeutics Inc shares are lower in after-market hours, showing unusual volatility and trading below its 20-day moving average. No specific news was identified.

14.09.2026 г., 20:07 ч. UTC

Social Media

Axsome Therapeutics shares are lower today, continuing a decline since Friday. Recent prescription data and a price target of $316 from Mizuho have not supported the stock.

12.09.2026 г., 00:01 ч. UTC

Social Media

Axsome Therapeutics shares rise in after-market trading, supported by Mizuho's $316 price target and positive prescription data for Auvelity.

11.09.2026 г., 20:01 ч. UTC

News
Social Media

Axsome Therapeutics shares rise following positive analyst commentary on Auvelity's launch and strong prescription growth, with unusually high trading volume today.

9.09.2026 г., 20:07 ч. UTC

Axsome Therapeutics Inc. shares are higher today, continuing a positive trend since Tuesday's close amid typical trading activity within its one-month range.

8.09.2026 г., 19:36 ч. UTC

Axsome Therapeutics Inc shares are higher today amid routine trading, with no specific company news identified. The stock has gained since Friday's close.

4.09.2026 г., 22:40 ч. UTC

Axsome Therapeutics Inc. shares are higher in after-market hours, recovering from an earlier pullback and achieving a notable return since Friday's close.

3.09.2026 г., 20:07 ч. UTC

Axsome Therapeutics Inc shares are trading lower today, with no specific news identified to explain the decline amid a broader market downturn.

2.09.2026 г., 20:01 ч. UTC

News

Axsome Therapeutics will participate in several upcoming investor conferences, boosting shares amid positive sentiment regarding its outreach efforts.

1.09.2026 г., 19:51 ч. UTC

Event
News

Axsome Therapeutics Inc. announced the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation, boosting shares higher.

31.08.2026 г., 21:02 ч. UTC

Event

Axsome Therapeutics shares rise in after-market hours following the dosing of the first patient in the SUMMIT Phase 3 trial for AXS-05.

29.08.2026 г., 00:01 ч. UTC

Axsome Therapeutics Inc is higher in after-market trading, advancing since Friday's close, though still below its 20-day moving average.

28.08.2026 г., 23:46 ч. UTC

Axsome Therapeutics Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. They remain below their 20-day moving average.

27.08.2026 г., 19:36 ч. UTC

Axsome Therapeutics Inc. shares are trading lower, continuing a decline since Wednesday and remaining near the lower end of their one-month trading range.

26.08.2026 г., 19:36 ч. UTC

Axsome Therapeutics Inc. shares are trading higher today, recovering from an early dip. The stock remains below its 20-day moving average.

25.08.2026 г., 21:01 ч. UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing down and trading below the 20-day moving average.

24.08.2026 г., 21:01 ч. UTC

Axsome Therapeutics Inc shares are lower in after-market trading. The stock has declined for four consecutive sessions and remains below its 20-day moving average.

21.08.2026 г., 19:41 ч. UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20.08.2026 г., 20:01 ч. UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17.08.2026 г., 19:16 ч. UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14.08.2026 г., 19:36 ч. UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13.08.2026 г., 19:56 ч. UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12.08.2026 г., 22:36 ч. UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11.08.2026 г., 19:45 ч. UTC

Social Media
News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10.08.2026 г., 23:06 ч. UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7.08.2026 г., 19:52 ч. UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6.08.2026 г., 23:01 ч. UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5.08.2026 г., 19:36 ч. UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Axsome Therapeutics Inc Прогноза

Ценова цел

By TipRanks

35.8% нагоре

12-месечна прогноза

Среден 291 USD  35.8%

Висок 380 USD

Нисък 251 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Axsome Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

12

Купи

1

Задържане

0

Продай

Настроение

By Acuity

2 / 339 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.